Bifidobacterium lactis

Bifidobacterium lactis (formally Bifidobacterium animalis subsp. lactis) is a gram-positive probiotic bacterium naturally found in the human gut and in fermented dairy foods like yogurt and kefir. It is one of the most extensively studied probiotic species and is commonly used to support digestive regularity, gut barrier integrity, and immune function. Clinically studied strains include Bb-12, HN019, Bi-07, and BI-04, each with distinct research profiles. It is often paired with other probiotics like [Lactobacillus acidophilus](/ingredients/lactobacillus-acidophilus) or [Lactobacillus plantarum](/ingredients/lactobacillus-plantarum) in multi-strain formulas such as [OPA Probiotic-40](/products/opa-probiotic-40-daily-probiotic).

Bifidobacterium lactis has a notably strong evidence base compared to many other probiotic species, with particularly robust support for digestive regularity (evidence score 8.9/10) and immune function enhancement (evidence score 8.4/10). Multiple randomized controlled trials using strains like Bb-12 and HN019 have demonstrated measurable improvements in stool frequency, consistency, and markers of immune response. Evidence for gut barrier integrity and infant gut health is also well-supported, while research on allergy and atopy modulation is promising but more preliminary (evidence score 6.3/10). Overall, it is considered one of the better-evidenced probiotic species available in supplement form.

Adults experiencing irregular bowel habits, bloating, or IBS-type symptoms may benefit most, as clinical trials have consistently shown improvements in stool frequency and consistency with regular supplementation. Older adults are also a key population, since Bifidobacterium species naturally decline with age and supplementation may help restore gut microbial balance. Infants and young children have a strong evidence base as well, with studies showing B. lactis may support healthy gut colonization and reduce gastrointestinal distress. People with compromised immune function or those recovering from antibiotic use are also commonly advised to consider B. lactis-containing probiotics.

The typical clinically studied dose range for Bifidobacterium lactis is 1–10 billion CFU per day (1×10⁹ – 1×10¹⁰ CFU), though some studies have used higher doses without reported safety concerns. Timing matters for survival: taking B. lactis with or just before a meal is generally recommended, as food buffers stomach acid and improves the number of viable bacteria that reach the intestine. Consistency over time — typically at least 4 weeks — appears more important than any single large dose. Products like [OPA Probiotic-40](/products/opa-probiotic-40-daily-probiotic) deliver 40 billion CFU across multiple strains, which falls within the range used in clinical research.

Bifidobacterium lactis has a well-established safety profile and is generally recognized as safe (GRAS) for healthy adults, children, and infants, with decades of use in commercial dairy products and supplements. The most commonly reported side effects are mild and transient, including gas or bloating during the first few days of supplementation as the gut microbiome adjusts. People who are immunocompromised, have a central venous catheter, or are critically ill should consult a healthcare provider before taking any live probiotic, as rare cases of bacteremia have been reported in highly vulnerable populations. There are no well-documented interactions with common medications, though taking B. lactis a few hours apart from antibiotics is generally advised to preserve viability.

Bifidobacterium lactis and [Fructooligosaccharides (FOS)](/ingredients/fructooligosaccharides) work through fundamentally different mechanisms: B. lactis is a live probiotic organism that directly colonizes the gut, while FOS is a prebiotic fiber that selectively feeds and promotes the growth of beneficial bacteria already present, including Bifidobacterium species. They are often used together because FOS can enhance the survival and activity of B. lactis in the colon — a combination sometimes called a synbiotic. While yogurt and kefir do contain B. lactis naturally, the CFU counts in most commercial dairy products are inconsistent and typically far lower than the 1–10 billion CFU used in clinical studies, making supplementation a more reliable way to achieve studied doses. If you prefer a food-first approach, look for products specifically labeled with live and active cultures and a declared CFU count at time of consumption.